The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Results from the Phase III CALGB/SWOG 80405 Trial

Richard Goldberg, MD
Published Online: 1:56 PM, Sun June 1, 2014
Richard Goldberg, MD, Physician-in-Chief at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, discusses results from the phase III CALGB/SWOG 80405 trial at the 2014 ASCO Annual Meeting. The CALGB/SWOG 80405 trial looked at irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated metastatic adenocarcinoma of the colon or rectum (mCRC).

<<< Back to the ASCO 2014 conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.